Efficacy and safety of potent P2Y12 inhibitors vs. clopidogrel in elderly patients with acute coronary syndrome

被引：0
|
作者：
Luo Li-Man
Pang Zhan-Qi
Fu Meng-Lu
Li Yuan-Yuan
Tu Ling
Xu Xi-Zhen
机构：
[1] China
[2] Dalian Municipal Central Hospital affiliated of Dalian Medical University
[3] Department of Cardiology
[4] Department of Geriatric Medicine
[5] Huazhong University of Science and Technology
[6] Hubei 430030
[7] Liaoning 116033
[8] Tongji Hospital
[9] Tongji Medical College
[10] Wuhan
来源：
中华医学杂志英文版 | 2020年 / 133卷 / 21期
基金：
中国国家自然科学基金;
关键词：
D O I：
暂无
中图分类号：
R541.4 [冠状动脉（粥样）硬化性心脏病（冠心病）];
学科分类号：
摘要：
To the Editor: Current guidelines recommended that patients with acute coronary syndrome (ACS) should receive dual anti-platelet therapy of aspirin plus P2Y12 inhibitors (clopidogrel, prasugrel, or ti
引用
收藏
页码：2628 / 2629
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of potent P2Y12 inhibitors vs. clopidogrel in elderly patients with acute coronary syndrome
    Luo, Li-Man
    Pang, Zhan-Qi
    Fu, Meng-Lu
    Li, Yuan-Yuan
    Tu, Ling
    Xu, Xi-Zhen
    CHINESE MEDICAL JOURNAL, 2020, 133 (21) : 2628 - 2629
  • [2] Efficacy and safety of newer P2Y12 inhibitors versus clopidogrel in patients with acute coronary syndrome
    Fei, Y.
    Lam, C.
    Cheung, B.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (07) : 1631 - 1631
  • [3] Potent P2Y12 inhibitors versus Clopidogrel in elderly patients with acute coronary syndrome: Systematic review and meta-analysis
    Fujisaki, Tomohiro
    Kuno, Toshiki
    Ando, Tomo
    Briasoulis, Alexandros
    Takagi, Hisato
    Bangalore, Sripal
    AMERICAN HEART JOURNAL, 2021, 237 : 34 - 44
  • [4] Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: A systematic review and meta-analysis
    Tarantini, Giuseppe
    Ueshima, Daisuke
    D'Amico, Gianpiero
    Masiero, Giulia
    Musumeci, Giuseppe
    Stone, Gregg W.
    Brener, Sorin J.
    AMERICAN HEART JOURNAL, 2018, 195 : 78 - 85
  • [5] Elderly patients are hyperresponsive to potent P2Y12 inhibitors
    Mutschlechner, D.
    Tscharre, M.
    Wadowski, P.
    Lee, S.
    Pultar, J.
    Weikert, C.
    Panzer, S.
    Gremmel, T.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [6] Meta-Analysis of the Relative Efficacy and Safety of Oral P2Y12 Inhibitors in Patients With Acute Coronary Syndrome
    Shah, Rahman
    Rashid, Abdul
    Hwang, Inyong
    Fan, Tai-Hwang M.
    Khouzam, Rami N.
    Reed, Guy L.
    AMERICAN JOURNAL OF CARDIOLOGY, 2017, 119 (11): : 1723 - 1728
  • [7] Potent P2Y12 inhibitors versus Clopidogrel in Cancer Patients undergoing Percutaneous Coronary Intervention
    Gitto, Mauro
    Sartori, Samantha
    Vogel, Birgit
    Leone, Pier Pasquale
    Smith, Kenneth
    Bay, Benjamin
    Krishnan, Prakash
    Sweeny, Joseph
    Oliva, Angelo
    Moreno, Pedro
    Di Muro, Francesca
    Krishnamoorthy, Parasuram
    Kini, Annapoorna
    Dangas, George
    Mehran, Roxana
    Sharma, Samin
    CIRCULATION, 2024, 150
  • [8] Novel Oral P2Y12 Inhibitor Prasugrel vs. Clopidogrel in Patients with Acute Coronary Syndrome: Evidence Based on 6 Studies
    Jia, Min
    Li, Zaibo
    Chu, Hongtao
    Li, Lin
    Chen, Keyong
    MEDICAL SCIENCE MONITOR, 2015, 21 : 1131 - 1137
  • [9] Efficacy and safety of newer P2Y12 inhibitors for acute coronary syndrome: a network meta-analysis
    Yue Fei
    Cheuk Kiu Lam
    Bernard Man Yung Cheung
    Scientific Reports, 10
  • [10] Efficacy and safety of newer P2Y12 inhibitors for acute coronary syndrome: a network meta-analysis
    Fei, Yue
    Lam, Cheuk Kiu
    Cheung, Bernard Man Yung
    SCIENTIFIC REPORTS, 2020, 10 (01)
12345